SI1718338T1 - Sestavki in metode za ciljno usmerjeno in vitro in in vivo dostavo zdravila v celice sesalcev preko bakterijsko pridobljenih intaktnih minicelic - Google Patents

Sestavki in metode za ciljno usmerjeno in vitro in in vivo dostavo zdravila v celice sesalcev preko bakterijsko pridobljenih intaktnih minicelic

Info

Publication number
SI1718338T1
SI1718338T1 SI200531990T SI200531990T SI1718338T1 SI 1718338 T1 SI1718338 T1 SI 1718338T1 SI 200531990 T SI200531990 T SI 200531990T SI 200531990 T SI200531990 T SI 200531990T SI 1718338 T1 SI1718338 T1 SI 1718338T1
Authority
SI
Slovenia
Prior art keywords
vitro
targeted
compositions
methods
drug delivery
Prior art date
Application number
SI200531990T
Other languages
English (en)
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Original Assignee
Engeneic Molecular Delivery Pty Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engeneic Molecular Delivery Pty Ltd. filed Critical Engeneic Molecular Delivery Pty Ltd.
Publication of SI1718338T1 publication Critical patent/SI1718338T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200531990T 2004-02-02 2005-01-27 Sestavki in metode za ciljno usmerjeno in vitro in in vivo dostavo zdravila v celice sesalcev preko bakterijsko pridobljenih intaktnih minicelic SI1718338T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54059004P 2004-02-02 2004-02-02
EP20050702361 EP1718338B1 (en) 2004-02-02 2005-01-27 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
PCT/IB2005/000204 WO2005079854A1 (en) 2004-02-02 2005-01-27 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells

Publications (1)

Publication Number Publication Date
SI1718338T1 true SI1718338T1 (sl) 2015-09-30

Family

ID=34885947

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531990T SI1718338T1 (sl) 2004-02-02 2005-01-27 Sestavki in metode za ciljno usmerjeno in vitro in in vivo dostavo zdravila v celice sesalcev preko bakterijsko pridobljenih intaktnih minicelic

Country Status (19)

Country Link
US (3) US9867785B2 (sl)
EP (2) EP1718338B1 (sl)
JP (2) JP5060787B2 (sl)
CN (2) CN102028953B (sl)
AU (2) AU2005215254B2 (sl)
CA (2) CA2788707C (sl)
DK (2) DK1718338T3 (sl)
ES (2) ES2765426T3 (sl)
HK (1) HK1155665A1 (sl)
HR (1) HRP20150828T8 (sl)
HU (1) HUE025292T2 (sl)
ME (1) ME02251B (sl)
NZ (1) NZ549139A (sl)
PL (1) PL1718338T3 (sl)
PT (1) PT1718338E (sl)
RS (1) RS54149B1 (sl)
SG (3) SG135174A1 (sl)
SI (1) SI1718338T1 (sl)
WO (1) WO2005079854A1 (sl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9044381B2 (en) 2003-06-24 2015-06-02 Baxter International Inc. Method for delivering drugs to the brain
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
CN102028953B (zh) 2004-02-02 2013-10-30 恩杰内克分子递送有限公司 经细菌来源的完整微细胞在体外和体内将药物靶向递送至哺乳动物细胞的组合物和方法
JP2008502706A (ja) 2004-06-15 2008-01-31 バクスター・インターナショナル・インコーポレイテッド 固体微粒子治療剤のエキソビボ適用
ES2535235T3 (es) 2004-08-26 2015-05-07 Engeneic Molecular Delivery Pty Ltd Administración de ácidos nucleicos funcionales a células de mamífero a través de minicélulas intactas obtenidas a partir de bacterias
CA2933978C (en) 2007-03-30 2018-08-21 Engeneic Molecular Delivery Pty. Ltd. Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
JP2010540466A (ja) 2007-09-24 2010-12-24 ザ ユニバーシティ オブ クイーンズランド 分子送達ベシクル
KR20180041269A (ko) * 2008-01-22 2018-04-23 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
RU2496482C2 (ru) 2008-03-05 2013-10-27 Бакстер Интернэшнл Инк. Композиции и способы для доставки лекарственных средств
KR101813824B1 (ko) 2008-06-25 2017-12-29 벡션 테라퓨틱스 엘엘씨 조절된 유전자 자살 메커니즘 조성물 및 방법
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
WO2011002239A2 (ko) 2009-07-01 2011-01-06 주식회사이언메딕스 포유류의 유핵세포에서 유래된 마이크로베시클 및 이의 용도
IT1401457B1 (it) * 2010-06-11 2013-07-26 Fond I R C C S Istituto Neurologico Carlo Besta Carrier di tipo cellulare per il trasporto mirato di almeno una molecola e/o almeno un composto molecolare ad almeno una cellula bersaglio in un mammifero umano o non umano
US9149542B2 (en) 2010-07-01 2015-10-06 Aeon Medix Inc. Microvesicles derived from cell protoplast and use thereof
DK2675474T3 (en) * 2011-02-15 2019-04-23 Vaxiion Therapeutics Llc THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES
SG11201403062YA (en) * 2011-12-13 2014-07-30 Engeneic Molecular Delivery Pty Ltd Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
JP6479662B2 (ja) 2012-10-02 2019-03-06 バキシオン セラピューティクス，リミテッド ライアビリティ カンパニー 免疫調節ミニ細胞および使用方法
US9733222B2 (en) * 2012-10-03 2017-08-15 Waters Technologies Corporation Rapid analysis of steroids and steroid derivatives
BR112015018877A2 (pt) * 2013-02-07 2017-08-22 Externautics Spa Método para preparar uma composição farmacêutica, e, composição farmacêutica imunogênica
US10314916B2 (en) 2013-06-11 2019-06-11 House Wellness Foods Corporation Carrier for delivery of substance to phagocytes
MX2016004285A (es) 2013-10-04 2016-07-08 Engeneic Molecular Delivery Pty Ltd Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma.
EP3200765A4 (en) * 2014-10-03 2018-05-30 EnGeneIC Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
CN104388459B (zh) * 2014-10-29 2017-03-08 四川农业大学 使细菌自主产微细胞的方法及一株自产微细胞细菌突变株
KR101708424B1 (ko) 2015-03-04 2017-02-20 전남대학교산학협력단 코리네박테리움 속 박테리아 및 이로부터 유래된 미니셀 그리고 이의 용도
KR101858840B1 (ko) 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
US10940112B2 (en) 2016-05-04 2021-03-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
EP3522935A4 (en) 2016-10-06 2020-05-13 EnGeneIC Molecular Delivery Pty Ltd. BACTERIAL MINICELLS FOR THE DELIVERY OF NUCLEIC ACID ADJUVANTS AND METHODS OF USE THEREOF
US11642362B2 (en) 2017-07-06 2023-05-09 National University Of Singapore Methods of inhibiting cell proliferation and METTL8 activity
WO2019204154A1 (en) 2018-04-18 2019-10-24 Reyoung Corporation Compositions and methods for treating liver cancer
WO2019217164A1 (en) 2018-05-09 2019-11-14 Reyoung Corporation Compositions and methods for treating cancer and other diseases
JP2021532106A (ja) 2018-07-23 2021-11-25 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド 細菌由来ミニ細胞を含む組成物およびそれを使用する方法
US20220151947A1 (en) * 2019-04-08 2022-05-19 University Of Massachusetts Localization of payload delivery systems to tumor sites via beacon cell targeting
WO2020222161A1 (en) * 2019-05-01 2020-11-05 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived intact minicells for theranostic applications
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN114053430A (zh) * 2020-07-29 2022-02-18 深圳先进技术研究院 一种负载纳米载药颗粒的细菌及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496778A (en) 1983-10-03 1985-01-29 Exxon Research & Engineering Co. Process for the hydroxylation of olefins using molecular oxygen, an osmium containing catalyst, a copper Co-catalyst, and an aromatic amine based promoter
CA1270198A (en) 1984-08-08 1990-06-12 Marcel B. Bally Encapsulation of antineoplastic agents in liposomes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
WO1996032930A1 (en) 1995-04-18 1996-10-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
WO2000063364A2 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
AU2001294520A1 (en) 2000-08-21 2002-03-04 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture
WO2002072759A2 (en) * 2001-03-07 2002-09-19 Children's Medical Center Corporation Method to screen peptide display libraries using minicell display
US7011946B2 (en) 2001-05-22 2006-03-14 Trustees Of Tufts College In vivo assay for identification of antimicrobial agents
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20030166099A1 (en) * 2001-06-05 2003-09-04 Sabbadini Roger A. Minicells comprising membrane proteins
CA2463631C (en) * 2001-10-15 2012-07-03 Engeneic Gene Therapy Pty Limited Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo
WO2003072014A2 (en) * 2002-02-25 2003-09-04 Mpex Bioscience, Inc. Minicell compositions and methods
US20030203481A1 (en) * 2002-02-25 2003-10-30 Surber Mark W. Conjugated minicells
US20030207833A1 (en) 2002-02-25 2003-11-06 Neil Berkley Pharmaceutical compositions with minicells
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
PL1694361T3 (pl) 2003-12-09 2011-08-31 Engeneic Molecular Delivery Pty Ltd Ukierunkowane dostarczanie genów do niefagocytujących komórek ssaczych z zastosowaniem nienaruszonych minikomórek pochodzących od bakterii
CN102028953B (zh) 2004-02-02 2013-10-30 恩杰内克分子递送有限公司 经细菌来源的完整微细胞在体外和体内将药物靶向递送至哺乳动物细胞的组合物和方法
ES2535235T3 (es) 2004-08-26 2015-05-07 Engeneic Molecular Delivery Pty Ltd Administración de ácidos nucleicos funcionales a células de mamífero a través de minicélulas intactas obtenidas a partir de bacterias
WO2006066048A2 (en) 2004-12-17 2006-06-22 Beth Israel Deaconess Medical Center Compositions for bacterial mediated gene silencing and methods of using same
PL2712618T3 (pl) 2006-06-23 2017-07-31 Engeneic Molecular Delivery Pty Ltd. Ukierunkowane dostarczanie leków, terapeutycznych kwasów nukleinowych i funkcjonalnych kwasów nukleinowych do komórek ssaczych przez nienaruszone, uśmiercone komórki bakteryjne

Also Published As

Publication number Publication date
EP1718338B1 (en) 2015-05-06
CA2556248A1 (en) 2005-09-01
AU2005215254B2 (en) 2009-11-12
SG135174A1 (en) 2007-09-28
EP1718338A4 (en) 2009-07-22
JP2007534667A (ja) 2007-11-29
US20180280311A1 (en) 2018-10-04
CN1925873A (zh) 2007-03-07
CN102028953B (zh) 2013-10-30
JP2011178798A (ja) 2011-09-15
CA2788707A1 (en) 2005-09-01
US9867785B2 (en) 2018-01-16
PT1718338E (pt) 2015-09-21
AU2005215254A1 (en) 2005-09-01
DK2992901T3 (da) 2020-01-27
AU2010200599A1 (en) 2010-03-11
DK1718338T3 (en) 2015-08-10
JP5571031B2 (ja) 2014-08-13
HK1155665A1 (en) 2012-05-25
JP5060787B2 (ja) 2012-10-31
CN1925873B (zh) 2011-02-09
US10799461B2 (en) 2020-10-13
HRP20150828T1 (en) 2015-09-11
WO2005079854A1 (en) 2005-09-01
US20180133163A1 (en) 2018-05-17
HRP20150828T8 (hr) 2016-04-22
CN102028953A (zh) 2011-04-27
HUE025292T2 (en) 2016-02-29
AU2010200599B2 (en) 2011-09-22
SG169373A1 (en) 2011-03-30
CA2556248C (en) 2013-04-02
EP1718338A1 (en) 2006-11-08
EP2992901A1 (en) 2016-03-09
NZ549139A (en) 2009-11-27
CA2788707C (en) 2014-02-25
PL1718338T3 (pl) 2015-12-31
US20140220116A1 (en) 2014-08-07
RS54149B1 (en) 2015-12-31
ES2544652T3 (es) 2015-09-02
EP2992901B1 (en) 2019-10-23
ES2765426T3 (es) 2020-06-09
SG135175A1 (en) 2007-09-28
ME02251B (me) 2015-12-31

Similar Documents

Publication Publication Date Title
HRP20150828T1 (en) Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
EP2195001A4 (en) METHOD FOR THE PRODUCTION AND USE OF A CELL-PENETRATING PEPTIDE FOR IMPROVED DELIVERY OF NUCLEIC ACIDS, PROTEINS, MEDICAMENTS AND ADENOVIRES ON TISSUES AND CELLS AND COMPOSITIONS AND KITS
EP1594883A4 (en) COVALENT MODIFICATION OF RNA FOR DISTRIBUTION IN VITRO / I AND IN VIVO / I
EP1791959A4 (en) DISPOSAL OF FUNCTIONAL NUCLEIC ACIDS ON MAMMALIAN CELLS OVER BACTERIA ORIGINAL INTACT MINIMIZERS
IL266122A (en) Stable serum-free cell-to-cell gene transfer and production of recombinant human proteins in human cell lines
IL243462A (en) Oligomers and phosphate-based conjugates for insertion of drugs into living cells and cell nuclei
EP1636385A4 (en) INHIBITION OF GENE FUNCTION BY IN VIVO DISTRIBUTION OF GENE EXPRESSION INHIBITORS BASED ON POLYNUCLEOTIDES IN MAMMALIAN CELLS
EP2049130A4 (en) SOFT TISSUE LOAD COMPOSITION COMPRISING AUTOLOGOUS CELL CULTURE PRODUCT DERIVED FROM DERMA AND HYALURONIC ACID
HK1079987A1 (zh) 使用細胞脫唾液酸決定簇和糖綴合物將細胞靶向組織和器官的方法和組合物
EP1934361A4 (en) METHODS OF REJUVENING IN VITRO AND IN VIVO CELLS
WO2007147014A3 (en) Method and systems for using biopolymer-based beads and hydrogels
WO2010062911A3 (en) Compositions and methods of functionally enhanced in vitro cell culture system
IL186535A0 (en) Pharmaceutical compositions for elimination of heterogeneous and mixed cell populations in tumors
WO2011082038A3 (en) Improved reprogramming compositions
IL202184A (en) A method for enhancing the expression of exogenous T cell sequences, a method based kit, a pharmacological preparation containing at least one stimulatory substance and an adeno viral vector containing the exogenous sequence
EP1791952A4 (en) COMPOSITIONS AND METHODS OF SELF-RENEWAL AND DIFFERENTIATION IN HUMAN EMBRYONAL STEM CELLS
EP1971355A4 (en) METHOD AND COMPOSITIONS FOR THE DISPOSAL OF ACTIVE SUBSTANCES WITH IMPROVED PHARMACOLOGICAL PROPERTIES
WO2006045116A3 (en) In vivo site-specific incorporation of n-acetyl-galactosamine amino acids in eubacteria
EP2145953A4 (en) ACELLULAR SYSTEM FOR THE SYNTHESIS OF PROTEINS FROM CULTURED MAMMAL CELLS
EP1589999A4 (en) POLYVINYL ETHER FOR THE ADMINISTRATION OF POLYNUCLEOTIDES IN MAMMALIAN CELLS
EP2069481A4 (en) GENETIC ASSEMBLY OF UNNATURAL AMINO ACIDS IN PROTEINS IN MAMMALIAN CELLS
EP2488210A4 (en) METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING IN VITO OR IN VITRO-ADMINISTERED OLIGONUCLEOTIDE MEDICAMENTS
EP2034954A4 (en) NON VIRAL COMPOSITIONS AND METHODS FOR TRANSFECTING IN VIVO INTESTINAL CELLS
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
EP1626755A4 (en) INTRAVENOUS DISPOSAL OF POLYNUCLEOTIDES ON CELLS IN THE LIMBS OF MAMMALS